Abstract
It is well established that intestinal microbiota play an important role in the pathogenesis of inflammatory bowel disease (IBD), including ulcerative colitis and Crohns disease. Various methods of altering the composition of intestinal microbiota have been examined. Recent evidence suggests that the administration of select prebiotics, probiotics and synbiotics may improve the clinical outcome of patients with IBD. In addition, IBD patients are well known to carry a higher risk of developing colorectal cancer due to chronic inflammation. Therefore, probiotics and/or prebiotics may be appropriate treatments for prophylactic use due to their physiologic characteristics and lack of obvious toxicity. This review summarizes the current experimental and clinical knowledge about the role of intestinal microbiota in IBD, the prevention of carcinogenesis related to IBD, and its importance as a target for new forms of neutraceutical therapy.
Keywords: Butyrate, Crohn's disease, microbiota, prebiotics, probiotics, synbiotics, ulcerative colitis
Current Pharmaceutical Design
Title: The Therapeutic Impact of Manipulating Microbiota in Inflammatory Bowel Disease
Volume: 15 Issue: 18
Author(s): Osamu Kanauchi, Keiichi Mitsuyama and Akira Andoh
Affiliation:
Keywords: Butyrate, Crohn's disease, microbiota, prebiotics, probiotics, synbiotics, ulcerative colitis
Abstract: It is well established that intestinal microbiota play an important role in the pathogenesis of inflammatory bowel disease (IBD), including ulcerative colitis and Crohns disease. Various methods of altering the composition of intestinal microbiota have been examined. Recent evidence suggests that the administration of select prebiotics, probiotics and synbiotics may improve the clinical outcome of patients with IBD. In addition, IBD patients are well known to carry a higher risk of developing colorectal cancer due to chronic inflammation. Therefore, probiotics and/or prebiotics may be appropriate treatments for prophylactic use due to their physiologic characteristics and lack of obvious toxicity. This review summarizes the current experimental and clinical knowledge about the role of intestinal microbiota in IBD, the prevention of carcinogenesis related to IBD, and its importance as a target for new forms of neutraceutical therapy.
Export Options
About this article
Cite this article as:
Kanauchi Osamu, Mitsuyama Keiichi and Andoh Akira, The Therapeutic Impact of Manipulating Microbiota in Inflammatory Bowel Disease, Current Pharmaceutical Design 2009; 15 (18) . https://dx.doi.org/10.2174/138161209788489195
DOI https://dx.doi.org/10.2174/138161209788489195 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
n-3 Polyunsaturated Fatty Acids as Signal Transduction Modulators and Therapeutical Agents in Cancer
Current Signal Transduction Therapy Genetic Polymorphisms of ATP-Binding Cassette Transporters ABCB1 and ABCC2 and their Impact on Drug Disposition
Current Drug Targets Usnic Acid Inhibits Proliferation and Migration through ATM Mediated DNA Damage Response in RKO Colorectal Cancer Cell
Current Pharmaceutical Biotechnology Literature Evidence and ARRIVE Assessment on Neuroprotective Effects of Flavonols in Neurodegenerative Diseases' Models
CNS & Neurological Disorders - Drug Targets Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets 3,4-Dihydroxypyrrolidine as Glycosidase Inhibitor
Current Topics in Medicinal Chemistry Editorial [(Drugs and the Upper and Lower Gastrointestinal Tract: From Inflammation To Malignancy)
Current Drug Metabolism New Developments in Targeted Analysis of Protein Posttranslational Modifications
Current Proteomics Synthesis, Characterization, Antimicrobial and Anticancer Studies of Metal Complexes of 2-methoxy-4-((3-methylpyridin-2-ylimino)methyl)phenol
Mini-Reviews in Medicinal Chemistry Computer Aided Drug Design Approaches to Develop Cyclooxygenase Based Novel Anti-Inflammatory and Anti-Cancer Drugs
Current Pharmaceutical Design New Approaches to Mechanism Analysis for Drug Discovery Using DNA Microarray Data Combined with KeyMolnet
Current Drug Discovery Technologies Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Nutrient Regulation of Tumor and Vascular Endothelial Cell Proliferation
Current Cancer Drug Targets Opportunities to Exploit Non-Neutralizing HIV-Specific Antibody Activity
Current HIV Research Urinary Tract Tumors, Biology and Risk for Artificial Sweeteners Use with Particular Emphasis on some South American Countries
Current Nutrition & Food Science Is Src a Viable Target for Treating Solid Tumours?
Current Cancer Drug Targets Cancer Prevention by Dietary Bioactive Components that Target the Immune Response
Current Cancer Drug Targets Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Age- Related Macular Degeneration
Current Drug Therapy Histone Deacetylase 2 in the Mouse Hippocampus: Attenuation of Age- Related Increase by Caloric Restriction
Current Alzheimer Research The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism